Last checked at 
(Alliance News) - Shares rose in Scancell Holdings PLC on Friday as it has selected its Covid-19 vaccine candidate SN14 for further development and clinical trials.
Shares in the novel immunotherapies developer were 14% higher at 13.68 pence on Friday in London.
The SN14 vaccine candidate targets both the SARS-CoV-2 nucleocapsid protein and the key receptor-binding domain of the spike protein. It is based on a modification of Scancell's ImmunoBody DNA vaccine technology.
Scancell had initially evaluated 15 vaccine candidates containing different S and N components for the best T cell and antibody responses. SN14 elicited high-titre anti-S virus neutralising antibodies together with high avidity T cells against both the S and N proteins.
In October, Scancell partnered with Cobra Biologics to conduct preliminary work for the manufacture of SN14, with the intention of commencing a phase one Covidity trial as soon as possible during 2021.
"We are very excited about our SN14 second generation Covid-19 vaccine which could have significant advantages over first generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long term protection," said Chief Scientific Officer Lindy Durrant.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
